WHO Expert Committee on Drug Dependence
Thirty-fifth Report
Technical Report Series, No 973
World Health Organization
ISBN-13    9789241209731 ISBN-10    9241209739
N░ de commande    11000973   
Prix    CHF    14.00 / US$    16.80 Pays en développement    CHF    9.80
Anglais     2012        32   pages
Table des matières
 
 
Sommaire
This report presents the recommendations of a WHO Expert Committee responsible for reviewing information on psychoactive substances to assess the need for their international control.

The report contains a summary of the Committee's evaluations of y-hydroxybutyric acid (GHB) and ketamine. GHB was recommended to be rescheduled from Scheduleá IV to Schedule II of the Convention on Psychotropic Substances.

The report also discusses the nine substances that were prereviewed: dextromethorphan, tapentadol, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP), 1-(3-chlorophenyl)piperazine (mCPP), 1-(4-methoxyphenyl) piperazine (MeOPP), 1-(3,4-methylenedioxybenzyl)piperazine (MDBP), y-butyrolactone (GBL), and 1,4-butanediol (1,4-BD). Of these, tapentadol, BZP, GBL and 1,4-BD were recommended for critical review. Issues identified for consideration at future Expert Committee meetings are also listed.

Furthermore, the report discusses the use of terms, the use of pharmacovigilance data for the assessment of abuse and dependence potential, balancing medical availability and prevention of abuse of medicines manufactured from controlled substances, and improving the process for substance evaluation.